Katherine Van Loon, MD, MPH

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
van-loon_katherine

Assistant Clinical Professor, University of California, San Francisco

Phone: (415) 353-9888
Box 1770, UCSF
San Francisco, CA 94143-1770

View on UCSF Profiles


Additional Websites


Education

Duke University    B.S.    05/00    Biology
Yale University    M.P.H.    05/02    Health Policy
Medical College of Georgia    M.D.    05/06    Medicine
Beth Israel Deaconess, Harvard Medical School    Intern    06/07    Internal Medicine
Beth Israel Deaconess, Harvard Medical School    Resident    06/09    Internal Medicine
University of California, San Francisco    Fellow    06/12    Oncology
 


Professional Experience

  • 2012-present
    Assistant Clinical Professor, Division of Hematology/Oncology, UCSF
  • 2011-2012
    Non-ACGME Fellow, Division of Hematology/Oncology, UCSF
  • 2009-2011
    ACGME Fellow, Division of Hematology/Oncology, UCSF

Honors & Awards

  • 2013
    NANETS Clinical Investigator Scholarship
  • 2013
    AHRQ K12 PARTNERS Program Scholar
  • 2012
    Young Investigator Award, ASCO Conquer Cancer Foundation
  • 2008
    Yale/Johnson & Johnson Physician Scholar in International Health, South Africa
  • 2008
    Nomination by Harvard Medical School Class of 2008 for Excellence in Teaching
  • 2002
    Dean’s Prize for Outstanding MPH Thesis, Yale University
  • 2001
    Weinerman Fellowship for Social Justice, Yale University
  • 2000
    Graduation with Distinction in Biology, Duke University
  • 2000
    Howard Hughes Undergraduate Fellowship in Neuroscience, Duke University

Selected Publications

  1. Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect. 2014 Nov 27.
    View on PubMed
  2. Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O'Reilly EM, Fuchs C, Innocenti F, Venook AP. 25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). J Natl Cancer Inst. 2014 Aug; 106(8).
    View on PubMed
  3. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol. 2014 Jul 25.
    View on PubMed
  4. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?: A Pooled Analysis of Phase II Trials of Gemcitabine-Containing Doublets Plus Bevacizumab. Pancreas. 2014 Apr; 43(3):343-9.
    View on PubMed
  5. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014 Jun 15; 120(12):1780-6.
    View on PubMed
  6. Van Loon K, Venook AP. Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities. J Clin Oncol. 2014 Apr 1; 32(10):991-6.
    View on PubMed
  7. Van Loon K, Venook AP. Biomarkers in colon cancer: the chasm between expectations and reality. Oncology (Williston Park). 2013 Aug; 27(8):758, 763.
    View on PubMed
  8. Van Loon K, Atreya CE, Kelley RK, Venook AP. Gene Profiling in Colon Cancer: How to Integrate Profiling into Practice. Personalized Medicine in Oncology. 2013; 2(4):204-11.
    View on PubMed
  9. Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JA. Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. Clin Colorectal Cancer. 2013 Jun; 12(2):95-102.
    View on PubMed
  10. Van Loon K, Venook AP. Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain. J Natl Compr Canc Netw. 2012 Nov 1; 10(11):1379-86.
    View on PubMed
  11. Van Loon K, Venook AP. Metastatic colorectal cancer: a curable disease. Oncology (Williston Park). 2012 Mar; 26(3):275-6, 282.
    View on PubMed
  12. Van Loon K, Gill RM, McMahon P, Chigurupati R, Siddiqi I, Fox L, Damon L, McCalmont TH, Jordan R, Wolf J. 20q- clonality in a case of oral sweet syndrome and myelodysplasia. Am J Clin Pathol. 2012 Feb; 137(2):310-5.
    View on PubMed
  13. Van Loon K, Venook AP. Adjuvant treatment of colon cancer: what is next? Curr Opin Oncol. 2011 Jul; 23(4):403-9.
    View on PubMed
  14. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A. 2001 Nov 6; 98(23):13288-93.
    View on PubMed

Go to UCSF Profiles, powered by CTSI